Screening for sources of interindividual pharmacokinetic variability in anticancer drug therapy: Utility of population analysis

Cancer Investigation

Volumn 19, Issue 1, 2001, Pages 57-64

  Kastrissios, H ^a   Ratain, M J ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; CYTARABINE; DOCETAXEL; EPIRUBICIN; ETOPOSIDE; HYDROXYUREA;

ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; CANCER CHEMOTHERAPY; CANCER RISK; COST EFFECTIVENESS ANALYSIS; CYTOTOXICITY; DNA POLYMORPHISM; HUMAN; MAJOR CLINICAL STUDY; MASS SCREENING; PATIENT CARE; PATIENT SELECTION; PRIORITY JOURNAL; REVIEW; RISK FACTOR;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; HUMANS; MODELS, THEORETICAL; VARIATION (GENETICS);

EID: 0035087010     PISSN: 07357907     EISSN: None     Source Type: Journal    
DOI: 10.1081/CNV-100000075     Document Type: Review

References (54)

1. Pharmacodynamics in cancer therapy
2. Pharmacokinetic optimisation of cancer chemotherapy. Effect on outcomes
3. Overview of recent topics in clinical pharmacology of anticancer agents
4. Clinical pharmacodynamics of anticancer drugs
5. Bayesian parameter estimation and population pharmacokinetics
6. Feedback control mechanisms for drug dosage optimisation: Concepts, classification and clinical application
7. Practical treatment guide for dose individualization in cancer chemotherapy
8. Population pharmacodynamic study of amonafide: A cancer and leukemia group B study
9. Pharmacogenetics and cancer chemotherapy
10. Aging and pharmacology
11. Individualized dosing of anticancer drugs and the role of therapeutic monitoring
12. A population pharmacokinetic model for docetaxel (Taxotere): Model building and validation
13. Opportunities for integration of pharmacokinetics, pharmacodynamics, and toxicokinetics in rational drug development
14. Cancer burden in the aged: An epidemiologic and demographic overview
15. Patterns of care related to age of men with prostate cancer
16. Patterns of care related to age of breast cancer patients
17. Concerns of special populations: Cancer and the aging population - A Meeting of the President's Cancer Panel, July 31, 1997
18. Population pharmacokinetics, NONMEM and the pharmacokinetic screen; one academic scientist's perspective
19. Discussion paper on the testing of drugs in the elderly
20. Premarketing observational studies of population pharmacokinetics of new drugs
21. Estimation of population characteristics of pharmacokinetic parameters from routine clinical data
22. An introduction to mixed effect modeling: Concepts, definitions and justification
23. Population approaches in drug development. Report on an expert meeting to discuss population pharmacokinetic/pharmacodynamic software
24. Population pharmacokinetics/dynamics
25. A three-step approach to combining bayesian regression and NONMEM population analysis: Application to midazolam
26. Building population pharmacokinetic - Pharmacodynamic models. I. Models for covariate effects
27. Practical experience and issues in designing and performing population pharmacokinetic/pharmacodynamic studies
28. On the recording of sample times and parameter estimation from repeated measures pharmacokinetic data
29. Pharmacokinetic considerations of variation in intermittent infusion-time duration
30. Oral chemotherapy: Rationale and future directions
31. A markov mixed effect regression model for drug compliance
32. Medication compliance as a feature in drug development
33. Interaction between structural, statistical, and covariate models in population pharmacokinetic analysis
34. The use of population pharmacokinetics in drug development
35. Evaluation of methods for estimating population pharmacokinetic parameters. III. Monoexponential model: Routine clinical pharmacokinetic data
36. Optimal sampling times for pharmacokinetic experiments
37. Designs for population pharmacodynamics: Value of pharmacokinetic data and population analysis
38. Comparison of some practical sampling strategies for population pharmacokinetic studies
39. Influence of age and gender on the pharmacokinetics and pharmacodynamics of remifentanil. I. Model development
40. Exploratory analysis of population pharmacokinetic data from clinical trials with application to isradipine
41. An evaluation of population pharmacokinetics in therapeutic trials. I. Comparison of methodologies
42. An evaluation of population pharmacokinetics in therapeutic trials. II. Detection of a drug-drug interaction
43. Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer
44. NONMEM population pharmacokinetic studies of cytosine arabinoside after high-dose and after loading bolus followed by continuous infusion of the drug in pediatric patients with leukemias
45. Prediction of carboplatin clearance from standard morphological and biological patient characteristics
46. A sequential bayesian algorithm for dose individualisation of carboplatin
47. Population pharmacokinetics of carboplatin in children
48. Population pharmacokinetics and pharmacodynamics of cisplatin in patients with cancer: Analysis with the NONMEM program
49. Variability in the pharmacokinetics of epirubicin: A population analysis
50. Population pharmacokinetics of total and unbound etoposide
51. Population pharmacokinetics of hydroxyurea in cancer patients